Our Pipeline

Best-in-Class, Oral Drugs for Inflammatory and Metabolic Diseases

Project

Lead Optimization

Pre-Clinical

Phase 1

Phase 2

Phase 3

ABP-671

URAT1 inhibitor for Chronic Gout

Gout & Hyperuricemia

Chronic Kidney Disease

Refactory Gout

ABP-6016

Multiple Targets for Liver Diseases

NASH

HBV

Xanthine Oxidase Inhibitors

Gout

Learn About ABP-671 for Chronic Gout

Learn About ABP-6016 for Liver Disease